argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies
November 20, 2024 01:00 ET
|
argenx SE
Phase 2 data establish proof-of-concept of efgartigimod SC in myositis Enrollment to continue in Phase 3 across all three subtypes (IMNM, ASyS, DM) under evaluation in ALKIVIAPotential for...
argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China
November 11, 2024 07:30 ET
|
argenx SE
First and only NMPA-approved treatment for patients with CIDP in China Second VYVGART Hytrulo indication approved in China November 11, 2024 – 7:30am ET Amsterdam, the Netherlands— argenx SE...
argenx to Participate at Upcoming Investor Conferences
November 05, 2024 01:00 ET
|
argenx SE
November 5, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,...
argenx Reports Third Quarter 2024 Financial Results and Provides Business Update
October 31, 2024 02:00 ET
|
argenx SE
$573 million in third quarter global net product sales CIDP global expansion on track, with decisions on approval under review in Japan, Europe, China, and Canada Management to host conference...
argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024
October 24, 2024 01:00 ET
|
argenx SE
October 24, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,...
argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions
October 15, 2024 01:00 ET
|
argenx SE
Long-term and real-world data of VYVGART® (efgartigimod alfa-fcab) and VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrate speed of onset, depth of response, and durability of...
argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy
September 19, 2024 01:00 ET
|
argenx SE
ADHERE was largest and most innovative clinical trial of CIDP patients to date VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrated reduction in disease progression, reduced...
argenx to Present at Upcoming Investor Conferences
August 28, 2024 01:00 ET
|
argenx SE
August 28, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,...
argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update
July 25, 2024 01:00 ET
|
argenx SE
$478 million in second quarter global net product sales First CIDP patients treated with VYVGART® Hytrulo following June 21st FDA approval On track to begin four additional registrational studies...
argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024
July 18, 2024 01:00 ET
|
argenx SE
July 18, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,...